Implementation of pharmacogenetic testing at the Robert-Bosch-Krankenhaus
Recruiting
- Conditions
- Diseases that are to be treated with a drug for which a PGx guideline has been published
- Registration Number
- DRKS00019021
- Lead Sponsor
- Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
• Adults aged 18 or older
• Ability to give independent informed consent
• Signed written informed consent
• actual or planned prescription of at least one of the concerned drugs
Exclusion Criteria
• Inability to give independent informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Within this project we will introduce pharmacogenetic testing to the daily hospital routine. A defined panel of different pharmacogenetic variants is included in the testing. The results of the pharmacogenetic testing will be linked to PGx guidelines (DPWAG, CPIC) providing dosing recommendations for the concerned drugs using the GIMS software. The resulting pharmacogenetic report will be made available for the attending physician. Important note: The therapy decision is the sole responsibility of the attending physician.
- Secondary Outcome Measures
Name Time Method Investigation of the acceptance of pharmacogenetic testing and the occurence of adverse drug reactions despite dosing according to pharmacogenetic profile in the outpatient setting.<br>